Enzyme Finance vs Symmetry: funds or Solana baskets (2026)

Enzyme Finance and Symmetry both help create tokenized investment products, but they solve different problems. Enzyme is broader fund infrastructure: Onyx supports issuing and administering tokenized funds, Blue is for managing decentralized strategies, and Myso supports on-chain options. Its products serve institutional issuers and asset managers as well as strategy users.

Symmetry focuses on tokenized baskets on Solana. A basket can include up to 100 assets and represent that exposure through one token. Its auction-based rebalancing and intent engine support automated portfolio actions. That makes it more specific than Enzyme, but potentially a closer fit for builders who want composable basket products.

Their scale and maturity signals differ. Enzyme reports about $94 million in TVL across three main chains. Symmetry has about $156,000 in TVL, and its V3 is in beta. Those figures do not determine product quality, but Symmetry’s smaller on-chain footprint and beta status warrant extra caution.

Enzyme’s fee details are not published. Onyx issuers are directed to a pricing page, while specific fees for Enzyme vaults are not publicly stated here. Vault managers may set management or performance fees, so users should read each vault’s terms before depositing. Network gas fees also apply.

Symmetry says building on the protocol is free and that protocol fees are dynamic, scaling with use. It does not publish specific fee percentages. Check the app and documentation for a basket’s charges before committing funds. Solana transaction costs and keeper bounties for intents may also apply in practice.

Neither protocol gives enough detail here to calculate the total cost of using a particular product. Do not treat Symmetry’s free-to-build statement as meaning every transaction or basket is cost-free. For Enzyme, distinguish platform or issuer pricing from any manager-set vault fees and blockchain gas. For both, check the relevant product terms before depositing or launching.

Both protocols have two audits listed, but neither publicly names the auditors or provides audit scope details here. Enzyme says it is SOC 2 certified and has operated for more than eight years. It also describes security, availability and confidentiality controls. These points do not remove smart-contract risk, and Enzyme does not provide incident history in these details.

Enzyme users also take on the risks of a vault manager’s strategy and any third-party protocols that strategy uses. Its compliance tooling can support issuers, but it does not make a particular fund compliant or guarantee regulatory approval. Issuers remain responsible for their obligations.

Symmetry users face smart-contract risk as well as dependencies on price oracles and keepers that execute intents. Oracle aggregation does not eliminate the possibility of errors or manipulation, and V3’s beta status adds uncertainty. Symmetry describes permission controls, cooldowns and in-kind deposits and redemptions, but its TVL is small, so liquidity may be thin for some baskets. Assess the basket and its risks before depositing.

Enzyme offers a product suite rather than a single basket tool. Onyx provides white-label fund issuance and administration, Blue supports strategies across more than 30 protocols and hundreds of assets, and Myso handles covered calls and cash-secured puts. APIs, SDKs and modular interfaces are aimed at businesses embedding products in their own systems. Its compliance features include investor whitelisting and transaction monitoring, though issuers retain regulatory responsibility.

Symmetry’s toolkit is centered on basket creation and automation. Users can set asset weights, then use Dutch-auction rebalancing, oracle aggregation and intents for actions such as limit orders, schedules and protective swaps. It also offers basket permissions and cooldowns, plus SDKs for bots, DAOs and multisigs. In-kind minting and redemption are designed so new deposits do not dilute existing holders.

For a fund operation with several product needs, Enzyme has the wider stated range. For a focused Solana basket with programmable rebalancing, Symmetry has the more directly relevant features.

Choose Enzyme Finance if you manage funds, issue tokenized products or need strategy infrastructure across Ethereum, Polygon and Arbitrum. It is the more natural fit for institutions and asset managers that value white-label tools, APIs and built-in compliance features. Its larger reported TVL may also matter to users comparing the protocols’ current footprints, though it does not guarantee safety or liquidity for a particular vault. Check pricing and vault terms before using it.

Choose Symmetry if your goal is to create or use tokenized baskets on Solana, especially when automated rebalancing and intents matter. Its basket design supports up to 100 assets, but the low TVL and beta status of V3 make careful evaluation important. Fees are dynamic, and exact percentages are not published.

If you need institutional fund administration, lean toward Enzyme. If you want a focused Solana basket tool and accept beta-stage risks, Symmetry is the closer match.